Dow Jones
29.134,99 -125,82 (-0,43%) Nasdaq
10.829,50 +26,58 (+0,25%) Nikkei 225
26.173,98 -397,89 (-1,50%) EUR/USD
0,9558 -0,0039 (-0,41%) BTC-EUR
19.639,51 -1.673,73 (-7,85%) CMC Crypto 200
429,53 -29,60 (-6,45%)
Global Blood Therapeutics, Inc. (0IVZ.L)
| Chiusura precedente | 67,83 |
| Aperto | 67,88 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 67,88 - 67,88 |
| Intervallo di 52 settimane | 67,88 - 67,88 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 43,902M |
| Beta (5 anni mensile) | 0,46 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -4,86 |
| Prossima data utili | 02 nov 2022 - 07 nov 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022
Congress Moves to Expand Funding for National Network of Specialized Treatment Centers and Community Organizations for Sickle Cell Disease PatientsSOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced its support for the Sickle Cell Disease Treatment Centers Act of 2022, which was introduced today and, if passed in its current form, would authorize for appropriations of $535 million in annual funding to support sickle cell d
- GlobeNewswire
GBT and Sickle Cell Disease Association of America to Host 11th Annual Sickle Cell Disease Therapeutics Conference
Keynote by Admiral Rachel Levine, M.D., Assistant Secretary for Health, U.S. Department of Health and Human ServicesSOUTH SAN FRANCISCO, Calif. and BALTIMORE, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA) will host the 11th Annual Sickle Cell Disease (SCD) Therapeutics Conference on Wednesday, September 14th. The virtual conference, which takes place during National Sickle Cell Awareness Mon
- GlobeNewswire
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion Potential to address the full spectrum of critical needs in the underserved sickle cell community Transaction valued at $68.50 per Global Blood Therapeutics share in cash, for a total enterprise value of approximately $5.4 billion NEW YORK and SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Pfize
